Tickers: XTSX:VPT, PINX:VPTDF
Tags: Heathcare, Technology
Toronto, Ontario / TheNewswire / November 12, 2018 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT) is pleased to announce that St. Michael's Hospital in Toronto, Canada, has ordered the AI based VMS+ complete heart analysis system for use in clinical evaluations of cardiac patients.
Dr. Howard Leong-Poi and Dr. Chi-Ming Chow are spearheading the VMS+ acquisition. Dr. Leong-Poi, is the Head of the Division of Cardiology at St. Michael's Hospital and a Clinician Scientist in the Keenan Research Centre for Biomedical Science. Dr. Chow is the Director of the Echocardiography Lab and has expertise in the development of innovative technologies in the practice of echocardiography. Both have clinical interests in cardiac imaging in ischemic heart disease and valvular heart disease.
"Artificial intelligence holds a great deal of promise for many clinical imaging applications and we are very excited to participate with this leading-edge technology to more accurately assess cardiac chamber volumes and function by echocardiography," commented Dr. Leong-Poi.
"We are very pleased to have the interest and commitment from such a high profile cardiac institution in our own backyard," commented Desmond Hirson, President of Ventripoint. "We believe that our AI technology and product in the hands of Drs. Leong-Poi and Chow will make a valuable difference to patient outcomes."
There are many potential applications for this innovative technology - including assessing ventricular volumes and function after percutaneous valve interventions, and in response to cancer chemotherapies, and tying these to clinical outcomes.
St. Michael's is a major teaching and research hospital with expertise in diverse areas of health care. The Cardiovascular Disease & Diabetes Research Program at St. Michael's Hospital is extensive, covering basic biomedical sciences, translational research, clinical and populations-based studies, and knowledge translation. Their researchers are actively involved in training future surgeon-scientists, developing national guidelines in cardiovascular and diabetes medicine, and working continuously toward the application of discoveries to cure disease, reduce morbidity and extend the life of patients.
About Ventripoint Diagnostics Ltd.
Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information, please contact:
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.
